Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with a capital raising
Mandate

Vinge advises Cinclus Pharma in connection with a capital raising

March 05, 2020 Capital Markets and Public M&A

Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of X842, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD).

Vinge’s team consisted primarily of Dain Hård Nevonen, Kristina Ekberg, Amanda Knutsson and Fredric Reissmüller.

Related

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

 Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025

Vinge has advised Stirling Square Capital Partners (“SSCP”) in connection with the sale of part of its holding in Infobric to KKR

 Pursuant to the transaction, KKR has become a significant owner, while SSCP will remain the largest owner.
October 15, 2025

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 1 billion

 Vinge has advised ABG Sundal Collier in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 1 billion, and parallel written procedure to increase the bond framework to SEK 2 billion.
October 15, 2025